Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | CDK4 | P11802 | 2/20 | 0.34 |
| ▸ | CCND1 | P24385 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.30 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25949230 | 0.84 | CYP2D6 (0.38) | CYP2D6HRH3CDK4CCND1CCNE1 | |
| SCHEMBL25948790 | 0.78 | SMN1; SMN2 (0.35) | SMN1; SMN2 | |
| SCHEMBL4549832 | 0.75 | CDK4 (0.50) | CYP2D6HRH3CDK4CCND1RPS6KA3 | |
| SCHEMBL10082654 | 0.74 | CDK2 (0.36) | CDK4CCND1CCNE1CDK2 | |
| SCHEMBL18493528 | 0.74 | CDK2 (0.36) | CDK4CCND1CCNE1CDK2 | |
| SCHEMBL25950536 | 0.74 | CRHR1 (0.31) | — | |
| SCHEMBL30730837 | 0.74 | HRH3 (0.41) | CYP2D6HRH3 | |
| SCHEMBL23016499 | 0.73 | RPS6KA3 (0.48) | CDK4CCND1RPS6KA3 | |
| SCHEMBL15249220 | 0.71 | CDK2 (0.41) | CDK4CCND1CCNE1CDK2 | |
| SCHEMBL4549920 | 0.71 | CDK2 (0.40) | CDK4CCND1CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381189-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230381189-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230364098-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230364098-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230248733-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | US | disclosed |
| US-11717523-B2 | Transient protection of normal cells during chemotherapy | G1 THERAPEUTICS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11717523-B2 | Transient protection of normal cells during chemotherapy | G1 THERAPEUTICS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230241059-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | G1 THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230241059-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | G1 THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-11654148-B2 | HSPC-sparing treatments for RB-positive abnormal cellular proliferation | G1 THERAPEUTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-8822683-B2 | CDK inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140142299-A1 | CDK Inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142306-A1 | CDK Inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142299-A1 | CDK Inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142306-A1 | CDK Inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20130237534-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237544-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237534-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237544-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| WO-2012061156-A1 | CDK INHIBITORS | TAVARES FRANCIS X (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237534-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | CYP2D6 640/4885HRH3 3656/4885CDK4 12/4885 |
| US-20230364098-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | RB1, CDK4, CDKN1A | CYP2D6 3805/4885HRH3 1830/4885CDK4 2/4885 |
| US-20230248733-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | MKI67, PCNA, HRAS | CYP2D6 4540/4885HRH3 1329/4885CDK4 16/4885 |
| US-20230381189-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | CDK6, CCNC, MCL1 | CYP2D6 1687/4885HRH3 2229/4885CDK4 6/4885 |
| US-20140142306-A1 | CDK Inhibitors | CDK3, CDK9, CDK6 | CYP2D6 640/4885HRH3 3656/4885CDK4 12/4885 |
| US-20230241059-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | CDK4, RB1, BTK | CYP2D6 2711/4885HRH3 2330/4885CDK4 1/4885 |
| US-20140142299-A1 | CDK Inhibitors | CDK3, CDK9, CDK6 | CYP2D6 640/4885HRH3 3656/4885CDK4 12/4885 |
| US-11654148-B2 | HSPC-sparing treatments for RB-positive abnormal cellular proliferation | RB1, CDK4, CDKN1A | CYP2D6 3805/4885HRH3 1830/4885CDK4 2/4885 |
| US-11717523-B2 | Transient protection of normal cells during chemotherapy | CDK6, CCNC, MCL1 | CYP2D6 1687/4885HRH3 2229/4885CDK4 6/4885 |
| US-20130237544-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | CYP2D6 640/4885HRH3 3656/4885CDK4 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.